• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Transgene S.A. (Euronext: TNG)

Transgene is a France-based biopharmaceutical company focused on the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The Company has four compounds in Phase II clinical trials: TG4010, JX594/TG6006, TG4001/RG3484 and TG4040 and one compound in Phase I clinical trial: TG4023. Transgene has entered into strategic collaborative agreements for the development of two of its immunotherapy products: - An option agreement with Novartis for an exclusive license to develop TG4010 for the treatment of various cancers, including non small cell lung cancer (NSCLC) - An in-licensing agreement with US-based Jennerex Biotherapeutics, Inc., to develop and market JX594 (JX594/TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based vectors. *

 

	Start	1979-01-01 established
	Group	Mérieux (Group)
	Industry	therapeutic vaccine
	Industry 2	immunotherapy
	Person	Archinard, Philippe (Transgene 200512 CEO)
	Region	Strasbourg
	Country	France
	Street	Boulevard Gonthier d’Andernach Parc d’Innovation d’Illkirch
	City	67405 Illkirch
	Tel	+33-3-8827-9100
		Address record changed: 2018-07-24
Basic data	Employees	D: 101 to 500 (2006-12-31)
	Currency	EUR
	Annual sales	28,019,000 (revenues, total (2007) 2007-12-31)
	Profit	-5,521,000 (2007-12-31)
	Cash	84,100,000 (2014-09-30)
		* Document for �About Section�: Transgene S.A.. (3/31/11). "Press Release: Transgene Announces Completion of Enrolment in HCVac (Phase II Trial) of TG4040 for the Treatment of Chronic Hepatitis C". Illkirch.
		Record changed: 2019-06-09

Advertisement

More documents for Mérieux (Group)

• [1] Keranova S.A.. (9/10/19). "Press Release: Keranova Raises €24m in Second Round of Financing". Saint-Etienne & Lyon....
• [2] bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile....
• [3] Transgene S.A.. (5/2/19). "Press Release: Transgene and AstraZeneca Enter into a Collaboration and Exclusive License Option Agreement for Innovative Invir.IO based Armed Oncolytic Immunotherapies". Strasbourg....
• [4] bioMérieux S.A.. (4/24/19). "Press Release: bioMérieux – First-Quarter 2019 Business Review". Marcy l’Étoile....
• [5] bioMérieux S.A.. (4/15/19). "Press Release: “Global-PPS”, a Survey of Antibiotic Use and Bacterial Resistance in Hospitals Worldwide, Tops the 200,000 Patients". Marcy l’Étoile & Antwerp....
• [6] bioMérieux S.A.. (4/1/19). "Press Release: University of Antwerp, bioMérieux, and Wellcome Trust to Coordinate VALUE-Dx, a European Public-Private Partnership to Fight Antimicrobial Resistance through Diagnostics". Antwerp, London & Marcy l’Eoile....
• [7] bioMérieux S.A.. (3/19/19). "Press Release: Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury". Deerfield, IL & Marcy l’Etoile....
• [8] bioMérieux S.A.. (2/27/19). "Press Release: bioMérieux – 2018 Financial Results"....
• [9] bioMérieux S.A.. (2/7/19). "Press Release: bioMérieux Acquires Invisible Sentinel, a US-based Company Specialized in Food and Beverage Molecular Testing". Marcy l’Étoile....
• [10] bioMérieux S.A.. (11/13/18). "Press Release: bioMérieux Launches the BioFire FilmArray Pneumonia Panels with FDA Clearance and CE Marking". Marcy l’Étoile....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.